Monday, July 9, 2018
Havana.- The Genetic Engineering and Biotechnology Center (CIGB) stands out for its contribution to Cuban health care for more than three decades of activity, with important benefits for the island and abroad.
Attached to the business group BioCubaFarma, the CIGB supplies products to prevent diseases, including the vaccines Heberbiovac against hepatitis B, and QuimiHib against meningitis caused by Haemophilus influenzae.
In addition, it produces the pentavalent vaccine and alpha and gamma interferon to control viral diseases, together with Heberprot-P, which has been administered in the country for 10 years.
Heberprot-P, the only drug of its kind in the world, has contributed to reducing the relative risk of amputation due to diabetic foot ulcers in about 70 percent of patients.
In addition, Heberferon, based on a combination of alpha and gamma interferon for the effective treatment of non-melanoma skin cancer, has been administered in 50 health units in Cuba.